167 related articles for article (PubMed ID: 35236732)
1. Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.
Okonogi N; Usui H; Murata K; Hori M; Kurokawa T; Fujiwara T; Fujii Y; Hanawa M; Kawasaki Y; Hattori Y; Suzuki K; Tsuyuki K; Wakatsuki M; Hasegawa S; Yamada S; Hanaoka H; Shozu M; Tsuji H
BMJ Open; 2022 Mar; 12(3):e056424. PubMed ID: 35236732
[TBL] [Abstract][Full Text] [Related]
2. A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results.
Okonogi N; Murata K; Yamada S; Habu Y; Hori M; Kurokawa T; Inaba Y; Fujiwara T; Fujii Y; Hanawa M; Kawasaki Y; Hattori Y; Suzuki K; Tsuyuki K; Wakatsuki M; Koto M; Hasegawa S; Ishikawa H; Hanaoka H; Shozu M; Tsuji H; Usui H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445743
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Monk BJ; Toita T; Wu X; Vázquez Limón JC; Tarnawski R; Mandai M; Shapira-Frommer R; Mahantshetty U; Del Pilar Estevez-Diz M; Zhou Q; Limaye S; Godinez FJR; Oppermann Kussler C; Varga S; Valdiviezo N; Aoki D; Leiva M; Lee JY; Sulay R; Kreynina Y; Cheng WF; Rey F; Rong Y; Ke G; Wildsmith S; Lloyd A; Dry H; Tablante Nunes A; Mayadev J
Lancet Oncol; 2023 Dec; 24(12):1334-1348. PubMed ID: 38039991
[TBL] [Abstract][Full Text] [Related]
4. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Mayadev J; Nunes AT; Li M; Marcovitz M; Lanasa MC; Monk BJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1065-1070. PubMed ID: 32447296
[TBL] [Abstract][Full Text] [Related]
5. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
[TBL] [Abstract][Full Text] [Related]
6. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.
Li J; Liu H; Li Y; Li J; Shen L; Long W; Yang C; Xu H; Xi W; Cai R; Feng W
Trials; 2022 Jan; 23(1):29. PubMed ID: 35012634
[TBL] [Abstract][Full Text] [Related]
7. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
Kok PS; Forde PM; Hughes B; Sun Z; Brown C; Ramalingam S; Cook A; Lesterhuis WJ; Yip S; O'Byrne K; Pavlakis N; Brahmer J; Anagnostou V; Ford K; Fitzpatrick K; Bricker A; Cummins MM; Stockler M; Nowak AK;
BMJ Open; 2022 Jan; 12(1):e057663. PubMed ID: 35078853
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
9. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001).
Okonogi N; Wakatsuki M; Kato S; Karasawa K; Kiyohara H; Shiba S; Kobayashi D; Nakano T; Kamada T; Shozu M;
Cancer Med; 2018 Feb; 7(2):351-359. PubMed ID: 29341491
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
[TBL] [Abstract][Full Text] [Related]
14. Carbon ion radiotherapy for mesonephric adenocarcinoma of the uterine cervix: a case report.
Kobayashi N; Oike T; Ando K; Murata K; Tamaki T; Noda SE; Kogure K; Nobusawa S; Oyama T; Ohno T
J Med Case Rep; 2024 May; 18(1):228. PubMed ID: 38720351
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis.
Niibe Y; Tsunoda S; Jobo T; Imai M; Matsuo K; Matsunaga K; Unno N; Hayakawa K
Eur J Gynaecol Oncol; 2008; 29(3):222-4. PubMed ID: 18592783
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
[TBL] [Abstract][Full Text] [Related]
17. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
18. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
[TBL] [Abstract][Full Text] [Related]
19. 'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
Rotman J; Mom CH; Jordanova ES; de Gruijl TD; Kenter GG
BMC Cancer; 2018 Sep; 18(1):888. PubMed ID: 30208866
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.
Ogasawara S; Koroki K; Makishima H; Wakatsuki M; Takahashi A; Yumita S; Nakagawa M; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Sakuma T; Fujita N; Kojima R; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Ozawa Y; Kawasaki Y; Kurokawa T; Hanaoka H; Tsuji H; Kato N
BMJ Open; 2022 Apr; 12(4):e059779. PubMed ID: 35396315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]